Thrombosis News and Research

Latest Thrombosis News and Research

OrbusNeich's Genous Stent safe, effective for patients at high risk of restenosis

OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte™ paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis.

17 Aug 2011

New tool can identify patients at high risk of venous thromboembolism

A new risk prediction tool can identify patients at high risk of serious blood clots (known as venous thromboembolism) who might need preventative treatment, says a study published on bmj.com today.

17 Aug 2011

DJOFL second quarter net sales increase 14.5% to $277.8 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the second quarter of fiscal 2011, ended July 2, 2011.

16 Aug 2011

Toclizumab for juvenile rheumatoid arthritis

The arthritis drug Toclizumab could be a boon for hundreds of children suffering from severe arthritis. It has been re-launched in children after being already licensed for the treatment of adults. At least two thirds of children taking tocizilumab have been able to return to a normal life, after many were bedridden or forced into wheelchairs by the disease, the clinical studies reveal.

16 Aug 2011

Female sex hormone oestrogen could fight against cardiovascular disease

The sex hormone oestrogen could help protect women from cardiovascular disease by keeping the body's immune system in check, new research from Queen Mary, University of London has revealed.

12 Aug 2011

Anticoagulation service improves quality of care for patients treated with warfarin

A pharmacist-directed anticoagulation service improves the coordination of care from the hospital to an outpatient clinic for patients treated with the anticoagulant drug warfarin, according to a Henry Ford Hospital study.

11 Aug 2011

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Eli Lilly and Company today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion.

10 Aug 2011

Cook Medical launches Doppler DP-M350 Blood Flow Monitor

In an effort to provide surgeons and nurses with an advanced tool to better monitor blood flow during free flap procedures, Cook Medical has launched the Doppler DP-M350 Blood Flow Monitor, a medical device at the forefront of transplant and reconstructive surgery.

8 Aug 2011

Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. presented data from its clinical development program for OBI-1, an intravenous (IV) recombinant porcine factor VIII product (rpFVIII), intended for the treatment of bleeding in people with hemophilia A with inhibitors and in people with acquired hemophilia.

28 Jul 2011

New preclinical data from Baxter's BAX 499 hemophilia study presented at ISTH

Baxter International Inc. announced today that new data from a series of studies on BAX 499, an investigational compound for potential subcutaneous hemophilia therapy, were presented this week during the 23rd annual congress of the International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan.

From Baxter International Inc. 27 Jul 2011

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its second quarter 2011 results.

26 Jul 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Biogen Idec and Swedish Orphan Biovitrum today announced Phase 1/2a trial data showing that the companies' long-lasting fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) was well tolerated and demonstrated an approximately 1.7-fold increase in half-life compared with Advate, a commercially-available factor VIII product, in 16 previously-treated patients with severe hemophilia A.

26 Jul 2011

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.

26 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Artegraft BCA superior to cuffed ePTFE for hemodialysis access

Artegraft, Inc. announces that a three-year prospective, randomized clinical study published in the June 2011 issue of the Journal of Vascular Surgery confirms the superiority of Artegraft Bovine Carotid Artery vascular grafts (BCA) to cuffed ePTFE grafts.

21 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

Series of articles explore recent evidence-based vascular medicine

As the population ages and obesity and diabetes increase, more people suffer from noncardiac vascular diseases. In the July/August issue of Progress in Cardiovascular Diseases, published by Elsevier, a series of articles from recognized experts on key topics in vascular disease and endovascular medicine provide an insightful compendium of the evidence available to help improve the care of this complex patient population.

20 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011

Six UC institutions to improve hospital care

A key component of health care reform involves the improvement of quality, access and value when delivering health services, particularly for patients admitted to a hospital. To help meet these needs, the University of California established the Center for Health Quality and Innovation, which provides financial support for health quality initiatives across the UC health system.

16 Jul 2011

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

BIOTRONIK announced today the start of an international study comparing the company's ORSIRO sirolimus-eluting coronary stent with Abbott Laboratory's XIENCE PRIME everolimus-eluting coronary stent. The first implantations in the study, called BIOFLOW-II, took place in Europe last week.

14 Jul 2011